Feb 21st 2013 - Edison Investment Research today published a report on Bionomics entitled "Raising BNC101’s Profile". In summary, the report says:
Bionomics has presented a comprehensive review of the supporting data that underpins its cancer stem cell programme, BNC101, at a leading conference in this rapidly emerging field. The material presented included data on BNC101’s activity (effectively the first public disclosure) in a colorectal cancer re-implantation model – designed to be selective for cancer stem cells (CSCs) – as well as a literature review on the LGR5 target. Bionomics is currently completing preclinical studies with BNC101 and expects to initiate Phase I trials in 2014.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
